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Abstract
Background: Previously, we demonstrated that OVA-loaded macrophages (OVA-Mφ) partially
suppress OVA-induced airway manifestations of asthma in BALB/c mice. In vitro studies showed that
OVA-Mφ start to produce IL-10 upon interaction with allergen-specific T cells, which might
mediate their immunosuppressive effects. Herein, we examined whether IL-10 is essential for the
immunosuppressive effects of OVA-Mφ  in vivo, and whether ex vivo stimulation of the IL-10
production by OVA-Mφ could enhance these effects.
Methods: Peritoneal Mφ were loaded with OVA and stimulated with LPS or immunostimulatory
sequence oligodeoxynucleotide (ISS-ODN) in vitro. The increase of IL-10 production was examined
and, subsequently, ex vivo stimulated OVA-Mφ were used to treat (i.v.) OVA-sensitized mice. To
further explore whether Mφ-derived IL-10 mediates the immunosuppressive effects, Mφ isolated
from IL-10-/- mice were used for treatment.
Results: We found that stimulation with LPS or ISS-ODN highly increased the IL-10 production
by OVA-Mφ (2.5-fold and 4.5-fold increase, respectively). ISS-ODN stimulation of OVA-Mφ
significantly potentiated the suppressive effects on allergic airway inflammation. Compared to
sham-treatment, ISS-ODN-stimulated OVA-Mφ suppressed the airway eosinophilia by 85% (vs.
30% by unstimulated OVA-Mφ), IL-5 levels in bronchoalveolar lavage fluid by 80% (vs. 50%) and
serum OVA-specific IgE levels by 60% (vs. 30%). Importantly, IL-10-/-Mφ that were loaded with OVA
and stimulated with ISS-ODN ex vivo, failed to suppress OVA-induced airway inflammation.
Conclusions:  These results demonstrate that Mφ-derived IL-10 mediates anti-inflammatory
responses in a mouse model of allergic asthma, which both can be potentiated by stimulation with
ISS-ODN.
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Background
Chronic asthma is driven and maintained by the persist-
ence of a subset of chronically activated memory T lym-
phocytes. The development of allergen-specific CD4+ T-
helper 2 (Th2) immunoresponses is responsible for the
cellular and molecular events underlying the initiation
and progression of allergic asthma [1,2]. The Th2 lym-
phocyte, therefore, is potentially an important target cell
for therapy in allergic asthma.
Dendritic cells (DC) are well defined as antigen present-
ing cells (APC) able to initiate and regulate T cell
responses [3]. Besides skewing T-cell responses into Th1
or Th2 responses [4], DC have been shown to mediate the
induction of antigen-specific regulatory T (Treg) cells, like
CD4+ Th3 cells and CD4+ T regulatory 1 (Tr1) cells [5,6].
Macrophages (Mφ), however, can also serve as APC and
play a pivotal role in controlling and directing immune
responses [7,8]. To exert these functions, Mφ express
MHC-II molecules and secrete a variety of mediators. By
secreting pro-inflammatory cytokines, such as IL-1, IL-6
and TNF-α, Mφ can trigger immune responses against
microbial pathogens [8,9]. Moreover, by releasing IL-12
Mφ can specifically skew immune responses towards Th1
responses [10-12]. Although Mφ favor the induction of
Th1 responses [13,14], it has also been demonstrated that
Mφ can induce differentiation of Th2 lymphocytes
[15,16]. Similar to DC, Mφ are nowadays thought to be
capable of suppressing immune responses by secreting
anti-inflammatory mediators, such as PGE2, TGF-β and IL-
10 [7,9,17].
In the lung, alveolar Mφ participate in the maintenance of
immunological homeostasis. By secreting pro-inflamma-
tory cytokines and chemokines they direct the recruitment
and activation of inflammatory cells, while they also play
a key role in dampening immune responses against non-
pathogenic antigens [9,18]. Alveolar Mφ have been shown
to suppress T-lymphocyte proliferation in vitro [19,20]
and APC-function of DC in vitro and in vivo [21]. Addi-
tionally, several studies have demonstrated that Mφ
induce tolerance against inhaled allergens, likely at the
level of allergen-specific T lymphocytes [22-24]. Interest-
ingly, selective elimination of alveolar Mφ potentiated IgE
Ab production in response to inhaled allergen, indicating
a key role for alveolar Mφ in tolerance against allergen
inhalation [25]. Moreover, we [26] and others [12,27]
demonstrated that treatment with allergen-loaded Mφ
effectively suppresses allergen-induced airway manifesta-
tions of asthma.
In vitro studies demonstrated that allergen-specific T cells
induced IL-10 production by OVA-loaded Mφ (OVA-Mφ),
suggesting that the immunosuppressive effects of OVA-
Mφ might be mediated by IL-10 [26]. In this study, we
investigated whether stimulation with toll like receptor 4
(TLR4)-ligand LPS [28] and the TLR9-ligand immunos-
timulatory sequence oligodeoxynucleotide (ISS-ODN)
[29] increases the IL-10 production by allergen-loaded Mφ
and, thereby, can potentiate their immunosuppressive
effects. Subsequently, using Mφ isolated from IL-10-/-
mice, we examined whether Mφ-derived IL-10 is crucial in
the suppression of allergen-induced allergic airway
inflammation.
Methods
Animals
Animal care and use were performed in accordance with
the guidelines of the Dutch Committee of Animal Experi-
ments. Specific pathogen-free (according to the Federa-
tion of European Laboratory Animal Science Associations
[30]) male BALB/c mice (6 wk old) were purchased from
Charles River (Maastricht, The Netherlands). The mice
were housed in macrolon cages in a laminar flow cabinet.
Breeding pairs of IL10-/- BALB/c mice were kindly pro-
vided by DNAX (Palo Alto, CA) and were housed in mac-
rolon cages with filter top. All mice were provided with
food and water ad libitum.
Materials
OVA (chicken egg albumin, grade V) and purified LPS
from Escherichia coli 0111:B4 were purchased from Sigma-
Aldrich (St. Louis, MO). CpG-containing phosphorothio-
ate ISS-ODN and control phosphorothioate mutated oli-
godeoxynucleotide were synthesized by Isogen Bioscience
BV (Maarsen, The Netherlands). The ISS-ODN used had
the sequence 5'-TGACTGTGAA-CGTTCGAGATGA-3' and
the mutated-ODN had the sequence 5'-TGACTGTGAA-
GGTTAGAGATGA-3' [31].
Loading and stimulation of Mφ
Peritoneal Mφ were isolated from naïve BALB/c mice as
described previously [26]. For in vitro experiments, Mφ
were plated in triplicate wells of a 96-well round-bot-
tomed plate (Greiner Bio-One GmbH, Kremsmuenster,
Austria) at 1 × 105 Mφ/well in RPMI 1640 enriched with
2% FCS, penicillin/streptomycin (all GIBCO BRL) and 50
µM β-mercaptoethanol (Sigma-Aldrich). Mφ were loaded
with 2 mg/mL OVA and stimulated with different concen-
trations of LPS, ISS-ODN or mutated-ODN, for 20 h at
37°C and 5% CO2. Subsequently, supernatants were har-
vested and the amount of IL-10 was determined using an
IL-10-specific sandwich ELISA. Stimulation with 10 µg/
mL LPS or 3 µg/mL ISS-ODN triggered the highest IL-10
production by Mφ.
For in vivo studies, 1 × 107 Mφ/mL were loaded with 2 mg/
mL OVA and were stimulated with 10 µg/mL LPS or 3 µg/
mL ISS-ODN. After incubation for 3 h at 37°C and 5%
CO2, the Mφ were extensively washed (3 times with 50 mLRespiratory Research 2004, 5:21 http://respiratory-research.com/content/5/1/21
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saline) to remove all residual soluble OVA, LPS, and ISS-
ODN.
Sensitization, treatment and challenge
Mice were sensitized to OVA by active sensitization with 7
i.p. injections of 10 µg OVA in 0.5 mL pyrogen-free saline
on alternate days [32]. Treatment was performed 17 days
after the last sensitization by administration (i.v.) of 3 ×
105 Mφ in 50 µl saline. As an additional control group,
mice were i.v. injected with 50 µL saline (sham treat-
ment). One week after treatment, mice were exposed to
OVA (2 mg/mL saline) aerosol challenges for 5 min on 8
consecutive days.
Determination of OVA-specific IgE levels in serum
Mice were sacrificed and were bled by cardiac puncture.
Subsequently, serum was collected and stored at -70°C
until analysis. OVA-specific IgE in serum was measured as
described [33]. A reference standard was obtained by i.p.
immunization of mice with OVA and arbitrarily assigned
a value of 1000 experimental units/mL (EU/mL). The
detection level of the IgE ELISA was 0.5 U/mL for IgE.
Analysis of the cellular composition in the bronchoalveolar 
lavage fluid
Bronchoalveolar lavage (BAL) was performed immedi-
ately after bleeding of the mice by lavage of the airways
through a tracheal cannula with 1 mL saline containing 2
µg/mL aprotinine (Roche Diagnostics) and 5% BSA
(Sigma-Aldrich). Cytokines in the supernatant of this first
mL of the BAL fluid (BALF) were determined by ELISA.
Subsequently, mice were lavaged 4 times with 1 mL saline.
The cells in the BALF were pooled in cold PBS (including
those from the first mL) and subsequently differentiated
into mononuclear cells (monocytes, Mφ and lym-
phocytes), eosinophils, and neutrophils as described pre-
viously [33].
Cytokine ELISAs
IL-5, IL-10, IL-12p70 ELISAs (all BD PharMingen) were
performed according to the manufacturer's instructions.
The detection limit of the IL-5 ELISA was 10 pg/mL, of the
IL-10 ELISA 15 pg/mL, and of the IL-12p70 ELISA 62.5 pg/
mL.
Statistical analysis
All data are expressed as mean ± standard error of mean
(SEM). Statistical analysis on BALF cell counts was per-
formed using the non-parametric Mann-Whitney U test
(2-tailed). For ELISA, results were statistical analyzed
using a Student's t test (2-tailed, homoscedastic). Results
were considered statistically significant at the P < .05 level.
Results
IL-10 production by Mφ is increased by LPS and ISS-ODN
In vitro studies suggest that the immunosuppressive effects
of OVA-Mφ could be mediated by Mφ-derived IL-10 [26].
To further enhance these immunosuppressive effects we
attempted to increase the IL-10 levels produced by Mφ.
Since Mφ express TLR4 and TLR9 [28,29], we tested
whether activation of these receptors (using LPS and ISS-
ODN, respectively) would increase the IL-10 production
by peritoneal Mφ. As Figure 1 shows, stimulation with LPS
or ISS-ODN highly increased the IL-10 production by
OVA-Mφ in vitro, while control mutated oligodeoxynucle-
otide did not. The IL-10 levels produced by OVA-Mφ
increased 2.5-fold upon stimulation with LPS and 4.5-
fold upon stimulation with ISS-ODN. IL-12p70 was not
detectable in any of these cultures (data not shown).
Increased production of IL-10 potentiates the suppressive 
effects of OVA-Mφ
To examine the in vivo effect of the increased production
of IL-10 by OVA-Mφ, peritoneal Mφ were isolated and sub-
sequently loaded with OVA and stimulated with LPS (10
µg/mL) or ISS-ODN (3 µg/mL) for 3 h. The stimulated
and OVA-loaded Mφ were administered (i.v.) to OVA-sen-
sitized mice.
In sham-treated mice, OVA-inhalation challenge strongly
increased OVA-specific IgE Ab in serum (Figure 2). Treat-
ment with OVA-Mφ that were not stimulated or stimu-
lated with LPS caused no significant suppression in the
up-regulation of serum OVA-specific IgE (Figure 2). In
LPS and immunostimulatory sequence oligodeoxynucleotide  (ISS-ODN) enhance the IL-10 production by OVA-Mφ Figure 1
LPS and immunostimulatory sequence oligodeoxynucleotide 
(ISS-ODN) enhance the IL-10 production by OVA-Mφ. 1 × 
105 Mφ/well were loaded with 2 mg/ml OVA and stimulated 
with either 10 µg/ml LPS or 3 µg/ml ISS-ODN for 20 h. As a 
control, Mφ were stimulated with mutated-ODN (M-ODN, 
3 µg/ml). One of four representative experiments is shown.
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contrast, ISS-ODN-stimulated OVA-Mφ significantly
suppressed (60%, P  < .05) the up-regulation of serum
OVA-specific IgE (Figure 2). OVA-specific IgG2a levels in
serum of sham-treated mice were also increased upon
OVA-inhalation challenge. However, these levels were not
affected upon treatment with OVA-Mφ or stimulated
OVA-Mφ (data not shown).
The BALF of mice, sensitized and challenged with OVA,
contained high numbers of eosinophils (Figure 3A). OVA-
Mφ partially suppressed (30%, not significant) the influx
of eosinophils into the BALF. Ex vivo stimulation of OVA-
Mφ with LPS further enhanced the suppression of airway
eosinophilia (60%, P < .05), compared with sham-treated
mice (Figure 3A). OVA-Mφ stimulated with ISS-ODN
effectively suppressed the airway eosinophilia. The
number of eosinophils in the BALF were significantly (P <
.01) suppressed by 85% compared to sham-treated mice
and by 79% compared to mice treated with OVA-Mφ (Fig-
ure 3A).
The BALF of sham-treated mice contained high levels of
the Th2 cytokine IL-5 (Figure 3B), that correlates with the
numbers of eosinophils. Treatment with OVA-Mφ or LPS-
stimulated OVA-Mφ reduced the IL-5 levels in the BALF by
50% (p = 0.07 and p = 0.06, respectively), compared to
sham-treated mice (Figure 3B). ISS-ODN-stimulated
OVA-Mφ, significantly reduced (P < .01) the IL-5 levels in
the BALF by 80%, compared to sham-treated mice. IL-10
was not detectable in the BALF of any of the mice (data
not shown).
Since ISS-ODN-stimulated OVA-Mφ produced the highest
levels of IL-10 and most strongly suppressed OVA-
induced airway inflammation, we used these Mφ to fur-
ther analyze the underlying mechanism of immunosup-
pression by allergen-loaded Mφ.
IL-10 produced by OVA-Mφ suppress OVA-induced airway 
inflammation
To prove that IL-10 produced by OVA-Mφ indeed medi-
ates the observed immunosuppressive effects, we isolated
peritoneal Mφ from IL-10-/- BALB/c mice. After loading
with OVA and stimulation with ISS-ODN ex vivo, the IL-
10-/- Mφ were administered (i.v.) to OVA-sensitized BALB/
c mice.
OVA-specific IgE levels in serum are significantly suppressed  upon treatment with ISS-ODN-stimulated and OVA-loaded  Mφ Figure 2
OVA-specific IgE levels in serum are significantly suppressed 
upon treatment with ISS-ODN-stimulated and OVA-loaded 
Mφ. OVA-sensitized BALB/c mice were treated (i.v.) with 
saline (sham), OVA-Mφ, ISS-ODN-stimulated OVA-Mφ (ISS-
ODN/OVA-Mφ), or LPS-stimulated OVA-Mφ (LPS/OVA-
Mφ). Subsequently, these mice were challenged by OVA inha-
lation. Serum OVA-specific IgE levels were measured prior 
to and after challenge. Values are expressed as the mean ± 
SEM (n = 6 to 8). *P < .05 compared with sham-treated and 
OVA-challenged mice. †P < .05 compared with mice treated 
with OVA-Mφ and that were OVA-challenged.
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ISS-ODN-stimulated and OVA-loaded Mφ (ISS-ODN/OVA-
Mφ) significantly suppress airway eosinophilia and IL-5 levels 
in the bronchoalveolar lavage fluid. The number of eosi-
nophils (eo), neutrophils (neutro) and mononuclear cells 
(MNC) in the BALF (A), and IL-5 levels in the BALF (B) after 
OVA inhalation challenge. Values are expressed as the mean 
± SEM (n = 6 to 8). *P < .01 and †P < .05 compared with 
sham-treated mice. ‡P < .01 and §P < .05 compared with mice 
treated with OVA-Mφ.
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Serum OVA-specific IgE levels of allergic mice that were
treated with ISS-ODN-stimulated IL-10-/- Mφ were as high
as that of sham-treated mice (Figure 4). However, the up-
regulation of serum OVA-specific IgE levels was partially
affected by ISS-ODN-stimulated IL-10-/- OVA-Mφ (Figure
4). The serum OVA-specific IgE levels were approximately
50% suppressed compared with unloaded ISS-ODN-stim-
ulated IL-10-/- Mφ. Still, these IgE levels were 45% higher
(P < .05) than in mice treated with ISS-ODN-stimulated
OVA-Mφ.
Importantly, after OVA-inhalation challenge, treatment
with ISS-ODN-stimulated IL-10-/- OVA-Mφ did not sup-
press airway eosinophilia (Figure 5A). Unloaded IL-10-/-
Mφ that were stimulated with ISS-ODN had also no effect
on airway eosinophilia, while immunotherapy with ISS-
ODN-stimulated OVA-Mφ suppressed the influx of eosi-
nophils by 88% (P < .05), compared to sham-treated mice
(Figure 5A).
The BALF of sham-treated mice, sensitized and challenged
with OVA, contained high levels of IL-5 (Figure 5B). Treat-
ment with ISS-ODN-stimulated IL-10-/- OVA-Mφ as well as
with ISS-ODN-stimulated IL-10-/- Mφ had no effect on the
IL-5 levels in the BALF (Figure 5B). In contrast, these IL-5
levels were significantly reduced by 78% (P < .05) upon
treatment with ISS-ODN-stimulated OVA-Mφ (Figure 5B).
Together, IL-10 produced by OVA-Mφ mediated the anti-
inflammatory effects of allergen-loaded Mφ on allergen-
induced airway eosinophilia and IL-5 production.
Discussion
Previously, we showed that allergen-loaded Mφ partially
suppress allergen-induced airway manifestations in mice
[26]. Here, we demonstrated that the anti-inflammatory
effects of allergen-loaded Mφ are IL-10 dependent and
that both the IL-10 production and the immunosuppres-
sive effects can be potentiated by stimulation of ISS-ODN.
Stimulation with ISS-ODN, a ligand for TLR9 [29], readily
increased the IL-10-production by peritoneal Mφ that
were loaded with OVA. In contrast, these Mφ produced no
detectable IL-12p70. We (data not shown) and others [34]
confirmed these data using the Mφ-like cell line
RAW264.7. In our mouse model of allergic asthma, stim-
The suppression of OVA-specific IgE in serum by ISS-ODN- stimulated and OVA-loaded Mφ is partially mediated by IL-10 Figure 4
The suppression of OVA-specific IgE in serum by ISS-ODN-
stimulated and OVA-loaded Mφ is partially mediated by IL-
10. Sensitized mice were treated (i.v.) with saline (sham), ISS-
ODN-stimulated OVA-Mφ (ISS-ODN/OVA-Mφ), ISS-ODN-
stimulated IL-10-/- Mφ (ISS-ODN/IL10-/-Mφ), or ISS-ODN-
stimulated IL-10-/- OVA-Mφ (ISS-ODN/IL10-/-OVA-Mφ). 
Serum OVA-specific IgE levels were measured prior to and 
after OVA challenge. Values are expressed as the mean ± 
SEM (n = 6 to 8 per group). *P < .05 compared with sham-
treated and OVA-challenged mice. †P < .05 compared with 
mice treated with ISS-ODN/IL10-/-OVA-Mφ and that were 
OVA-challenged.
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ulation of OVA-Mφ with ISS-ODN significantly
potentiated their immunosuppressive effects. The sup-
pression of the OVA-induced serum OVA-specific IgE lev-
els, airway eosinophilia and IL-5 levels in the BALF was
enhanced. Measuring the enhanced pause (Penh) in
response to inhalation of different doses of methacholine
(data not shown), we confirmed our previous finding that
OVA-Mφ significantly suppressed OVA-induced airway
hyperresponsiveness to methacholine [26]. As potentia-
tion of the IL-10 production by Mφ (using LPS or ISS-
ODN) did not further suppress the allergen-induced air-
way hyperresponsiveness (data not shown), it can be spec-
ulated that the mechanisms underlying the suppression of
airway hyperresponsiveness and of allergic airway inflam-
mation, at least in part, differ. However, we would like to
stress that Penh values may not correlate with changes in
pulmonary resistance [35].
Compared to ISS-ODN, stimulation with LPS showed an
intermediate capacity to enhance the immunosuppressive
effects of OVA-Mφ. OVA-Mφ produced higher levels of IL-
10 upon stimulation with ISS-ODN compared to stimula-
tion with LPS, suggesting a correlation between the levels
of IL-10 produced by the Mφ and the extent of suppression
of allergen-induced airway inflammation. As LPS and ISS-
ODN trigger signaling via different intracellular pathways
[36], we hypothesized that stimulation of Mφ with a com-
bination of LPS and ISS-ODN could further increase the
production of IL-10. However, the levels of IL-10 pro-
duced by OVA-Mφ stimulated with LPS and ISS-ODN
were as high as when stimulated with ISS-ODN only (data
not shown). Implying that stimulation of Mφ with ISS-
ODN results in maximal production of IL-10.
Using Mφ isolated from IL-10-/- BALB/c mice, we demon-
strated that Mφ-derived IL-10 is crucial in the suppression
of airway eosinophilia and IL-5 levels in the BALF, while
the suppression of serum IgE is partially IL-10 dependent.
Although a lack of IL-10 production could up-regulate the
MHC class II and B7 expression in Mφ of IL-10-/- mice, as
increased IL-10 levels could down-regulate these mole-
cules [37,38], the shift in expression of these molecules
will most probably not be the underlying mechanism of
suppression of airway eosinophilia and Th2 cytokines,
because low levels of MHC class II or B7 itself do not
result in suppressive functions. Furthermore, we can not
exclude that there are, at present unknown, developmen-
tal changes in Mφ derived from IL-10-deficient mice, that
may affect their capacity to suppress an allergic inflamma-
tory response. The observation that the suppression of IgE
is partially IL-10 independent suggests that the suppres-
sion of serum IgE levels is only slightly correlated to Th2-
cytokine levels. This is in agreement with the finding that
memory IgE responses are inferior mediated by Th2
cytokines [39]. These data indicate that a second, IL-10
independent, suppressive pathway has to be induced by
OVA-Mφ that causes a further suppression of serum IgE
levels.
Mφ can reside for long period of time in tissue, including
the lung [40]. By secreting the immunosuppressive
cytokine IL-10 the Mφ could, allergen-independently, sup-
press allergen-induced airway inflammation. In the past,
IL-10 has been shown to suppress allergen-induced airway
manifestations of asthma in the mouse [41-43]. However,
we found that, after i.v. treatment, the ISS-ODN-stimu-
lated OVA-Mφ specifically migrate to the spleen of OVA-
sensitized mice. Subsequently, at this site, an allergen-spe-
cific and long-lasting immunosuppressive response is
induced (preliminary results by Vissers JLM et al). These
results demonstrate that the IL-10 produced by the Mφ is
not directly responsible for the suppression of allergic
inflammation in the lungs, but that an allergen-specific
suppressive T-cell subset is induced in the spleen. This
hypothesis is supported by the finding that IL-10 produc-
tion by OVA-Mφ, upon recognition of OVA-specific T cells
in vitro, is dependent on MHC class II/TCR interaction
[26].
Direct targeting of OVA to alveolar Mφ, for instance by
intratracheal treatment with OVA-loaded liposomes,
could demonstrate whether Mφ in the lung can directly
induce suppression of OVA-induced airway inflamma-
tion. However, we (data not shown) and others [44]
found that alveolar Mφ from OVA-sensitized mice do not
produce IL-10 upon stimulation with LPS or ISS-ODN.
Although we were not able to test the suppressive capacity
of OVA-loaded alveolar Mφ in our mouse model, targeting
of allergens to alveolar Mφ could still be promising to
induce immunosuppressive effects in humans, because
alveolar Mφ from patients with allergic asthma produce
IL-10 [45,46].
In this study and in our previous study [26], we observed
no indications for an increased Th1 response upon immu-
notherapy with OVA-Mφ that could counteract the Th2
response. In contrast, others demonstrated that allergen-
loaded Mφ, stimulated with IFN-γ  ex vivo, promote a
switch from Th2 cells to Th1 cells [12,27]. This dissimilar-
ity can mainly be explained by the difference in cytokines
which are produced by the Mφ used. IFN-γ-stimulated Mφ
produce IL-12 upon allergen-specific interaction with T
cells [12], while our Mφ produce IL-10 upon antigen rec-
ognition [26]. Likely, IL-12 will favor skewing towards
Th1 [4,11], whereas IL-10 will act as a suppressive
cytokine. In our model, allergen-loaded Mφ will, most
probably, induce Treg cells via secretion of IL-10. Antigen-
induced Treg cells are typically induced in microenviron-
ments with APCs presenting antigens and local high levels
of IL-10 [6]. This T-cell subset plays a pivotal role in theRespiratory Research 2004, 5:21 http://respiratory-research.com/content/5/1/21
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maintenance of T-cell tolerance against foreign-antigens.
They exhibit their suppressive activity by secreting the sup-
pressive cytokine IL-10 (Tr1 cells) or TGF-β (Th3 cells)
[47]. By using CD4+ T lymphocytes, ex vivo transduced to
express IL-10, it was shown that allergen-specific lym-
phocytes can suppress allergen-induced asthma manifes-
tations via production of IL-10 [43]. Recently, Akbari and
colleagues found that pulmonary dendritic cells from
mice exposed to respiratory allergen produced IL-10 and,
thereby, induced allergen-specific Tr1 cells [5,48]. Fur-
thermore, treatment of mice with killed Mycobacterium
vaccae induced allergen-specific Treg cells that produced
IL-10 and TGF-β [49]. In agreement with our study, these
studies indicate a pivotal role for IL-10 in limiting aller-
gen-induced asthma manifestations.
Conclusions
Here, we demonstrated, in a mouse model of allergic air-
way inflammation, that treatment with allergen-loaded
Mφ suppress asthma manifestations in an IL-10-depend-
ent manner. Importantly, the IL-10 production and anti-
inflammatory effects of allergen-loaded Mφ can be poten-
tiated by stimulation with ISS-ODN. Further detailed
analysis of the mechanisms underlying this Mφ-based
immunotherapy may lead to the development of new
strategies to induce tolerance against allergen-specific Th2
responses in allergic diseases, including asthma.
Authors' contributions
JLMV carried out the allergic model, subsequent analysis,
writing and preparation of the manuscript. BCAMvE, PVJ
and GAH assisted with the allergic model. AJMvO partici-
pated in the direction of the study as well as writing and
preparing the manuscript. All authors read and approved
the final manuscript.
Acknowledgments
This study was supported by research grants 3.2.00.48 (JLMV) and 3.2.99.23 
(PVJ) from The Dutch Asthma Foundation and by Stichting Astma Bestri-
jding (BCAMvE). We thank Dr. D. Rennick (DNAX) for providing us the 
breeding pairs of IL10-/- BALB/c mice. We thank Dr. Nanne Bloksma for 
stimulating discussions and Dr. Sue McKay for critical reading of the 
manuscript.
References
1. Romagnani S: Human TH1 and TH2 subsets: regulation of dif-
ferentiation and role in protection and immunopathology. Int
Arch Allergy Immunol 1992, 98:279-285.
2. Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM,
Corrigan C, Durham SR, Kay AB: Predominant TH2-like bron-
choalveolar T-lymphocyte population in atopic asthma. N
Engl J Med 1992, 326:298-304.
3. Banchereau J, Steinman RM: Dendritic cells and the control of
immunity. Nature 1998, 392:245-252.
4. Hilkens CM, Kalinski P, de Boer M, Kapsenberg ML: Human den-
dritic cells require exogenous interleukin-12-inducing fac-
tors to direct the development of naive T-helper cells
toward the Th1 phenotype. Blood 1997, 90:1920-1926.
5. Akbari O, DeKruyff RH, Umetsu DT: Pulmonary dendritic cells
producing IL-10 mediate tolerance induced by respiratory
exposure to antigen. Nat Immunol 2001, 2:725-731.
6. Weiner HL: The mucosal milieu creates tolerogenic dendritic
cells and TR1 and TH3 regulatory cells.  Nat Immunol 2001,
2:671-672.
7. Goerdt S, Orfanos CE: Other functions, other genes: alterna-
tive activation of antigen-presenting cells.  Immunity 1999,
10:137-142.
8. Gordon S: Alternative activation of macrophages.  Nat Rev
Immunol 2003, 3:23-35.
9. Laskin DL, Weinberger B, Laskin JD: Functional heterogeneity in
liver and lung macrophages. J Leukoc Biol 2001, 70:163-170.
10. Sibille Y, Reynolds HY: Macrophages and polymorphonuclear
neutrophils in lung defense and injury. Am Rev Respir Dis 1990,
141:471-501.
11. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM:
Development of TH1 CD4+ T cells through IL-12 produced
by Listeria-induced macrophages. Science 1993, 260:547-549.
12. Desmedt M, Rottiers P, Dooms H, Fiers W, Grooten J: Macro-
phages induce cellular immunity by activating Th1 cell
responses and suppressing Th2 cell responses. J Immunol 1998,
160:5300-5308.
13. Brewer JM, Richmond J, Alexander J: The demonstration of an
essential role for macrophages in the in vivo generation of
IgG2a antibodies. Clin Exp Immunol 1994, 97:164-171.
14. Tang C, Inman MD, van Rooijen N, Yang P, Shen H, Matsumoto K,
O'Byrne PM: Th type 1-stimulating activity of lung macro-
phages inhibits Th2-mediated allergic airway inflammation
by an IFN-gamma-dependent mechanism.  J Immunol 2001,
166:1471-1481.
15. Peterson JD, Herzenberg LA, Vasquez K, Waltenbaugh C: Glutath-
ione levels in antigen-presenting cells modulate Th1 versus
Th2 response patterns.  Proc Natl Acad Sci U S A 1998,
95:3071-3076.
16. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM: M-1/M-2 macro-
phages and the Th1/Th2 paradigm.  J Immunol 2000,
164:6166-6173.
17. Grbic JT, Mannick JA, Gough DB, Rodrick ML: The role of prostag-
landin E2 in immune suppression following injury. Ann Surg
1991, 214:253-263.
18. Thepen T, Kraal G, Holt PG: The role of alveolar macrophages
in regulation of lung inflammation.  Ann N Y Acad Sci 1994,
725:200-206.
19. Strickland DH, Thepen T, Kees UR, Kraal G, Holt PG: Regulation of
T-cell function in lung tissue by pulmonary alveolar
macrophages. Immunology 1993, 80:266-272.
20. Upham JW, Strickland DH, Bilyk N, Robinson BW, Holt PG: Alveo-
lar macrophages from humans and rodents selectively
inhibit T-cell proliferation but permit T-cell activation and
cytokine secretion. Immunology 1995, 84:142-147.
21. Holt PG, Oliver J, Bilyk N, McMenamin C, McMenamin PG, Kraal G,
Thepen T: Downregulation of the antigen presenting cell func-
tion(s) of pulmonary dendritic cells in vivo by resident alveo-
lar macrophages. J Exp Med 1993, 177:397-407.
22. Holt PG, Batty JE, Turner KJ: Inhibition of specific IgE responses
in mice by pre-exposure to inhaled antigen. Immunology 1981,
42:409-417.
23. McMenamin C, Holt PG: The natural immune response to
inhaled soluble protein antigens involves major histocom-
patibility complex (MHC) class I-restricted CD8+ T cell-
mediated but MHC class II-restricted CD4+ T cell-depend-
ent immune deviation resulting in selective suppression of
immunoglobulin E production. J Exp Med 1993, 178:889-899.
24. Seymour BW, Gershwin LJ, Coffman RL: Aerosol-induced immu-
noglobulin (Ig)-E unresponsiveness to ovalbumin does not
require CD8+ or T cell receptor (TCR)-gamma/delta+ T
cells or interferon (IFN)-gamma in a murine model of aller-
gen sensitization. J Exp Med 1998, 187:721-731.
25. Thepen T, McMenamin C, Girn B, Kraal G, Holt PG: Regulation of
IgE production in pre-sensitized animals: in vivo elimination
of alveolar macrophages preferentially increases IgE
responses to inhaled allergen.  Clin Exp Allergy 1992,
22:1107-1114.
26. Janssen EM, Wauben MHM, Nijkamp FP, van Eden W, Van Ooster-
hout AJM: Immunomodulatory effects of antigen-pulsed mac-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Respiratory Research 2004, 5:21 http://respiratory-research.com/content/5/1/21
Page 8 of 8
(page number not for citation purposes)
rophages in a murine model of allergic asthma. Am J Respir Cell
Mol Biol 2002, 27:257-264.
27. Pynaert G, Rottiers P, Haegeman A, Sehra S, Van-Belle T, Korf J,
Grooten J: Antigen presentation by local macrophages pro-
motes nonallergic airway responses in sensitized mice. Am J
Respir Cell Mol Biol 2003, 29:634-41.
28. Medzhitov R: Toll-like receptors and innate immunity. Nature
Rev Immunol 2001, 1:135-145.
29. Wagner H: Interactions between bacterial CpG-DNA and
TLR9 bridge innate and adaptive immunity. Curr Opin Microbiol
2002, 5:62-69.
30. Nicklas W, Baneux P, Boot R, Decelle T, Deeny AA, Fumanelli M, Ill-
gen-Wilcke B: Recommendations for the health monitoring of
rodent and rabbit colonies in breeding and experimental
units. Lab Anim 2002, 36:20-42.
31. Roman M, Martin-Orozco E, Goodman JS, Nguyen MD, Sato Y, Ron-
aghy A, Kornbluth RS, Richman DD, Carson DA, Raz E: Immunos-
timulatory DNA sequences function as T helper-1-
promoting adjuvants. Nat Med 1997, 3:849-854.
32. Hessel EM, Van Oosterhout AJM, Hofstra CL, de Bie JJ, Garssen J, Van
Loveren H, Verheyen AK, Savelkoul HF, Nijkamp FP: Bronchocon-
striction and airway hyperresponsiveness after ovalbumin
inhalation in sensitized mice. Eur J Pharmacol 1995, 293:401-412.
33. Van Oosterhout AJM, Van Esch B, Hofman G, Hofstra CL, Van AI,
Nijkamp FP, Kapsenberg ML, Savelkoul HF, Weller FR: Allergen
immunotherapy inhibits airway eosinophilia and hyperre-
sponsiveness associated with decreased IL-4 production by
lymphocytes in a murine model of allergic asthma. Am J Respir
Cell Mol Biol 1998, 19:622-628.
34. Yi AK, Yoon JG, Yeo SJ, Hong SC, English BK, Krieg AM: Role of
mitogen-activated protein kinases in CpG DNA-mediated
IL-10 and IL-12 production: central role of extracellular sig-
nal-regulated kinase in the negative feedback loop of the
CpG DNA-mediated Th1 response.  J Immunol 2002,
168:4711-4720.
35. Bates J, Irvin C, Brusasco V, Drazen J, Fredberg J, Loring S, Eidelman
D, Ludwig M, Macklem P, Martin J, Milic-Emili J, Hantos Z, Hyatt R,
Lai-Fook S, Leff A, Solway J, Lutchen K, Suki B, Mitzner W, Pare P,
Pride N, Sly P: The use and misuse of Penh in animal models of
lung disease. Am J Respir Cell Mol Biol 2004, 31:373-374.
36. Ahmad-Nejad P, Hacker H, Rutz M, Bauer S, Vabulas RM, Wagner H:
Bacterial CpG-DNA and lipopolysaccharides activate Toll-
like receptors at distinct cellular compartments. Eur J Immunol
2002, 32:1958-1968.
37. De Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE:
Interleukin 10 (IL-10) inhibits cytokine synthesis by human
monocytes: an autoregulatory role of IL-10 produced by
monocytes. J Exp Med 1991, 174:1209-1220.
38. Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM: IL-10 inhib-
its macrophage costimulatory activity by selectively
inhibiting the up-regulation of B7 expression. J Immunol 1993,
151:1224-1234.
39. Van Ommen R, Vredendaal AE, Savelkoul HF: Secondary IgE
responses in vivo are predominantly generated via gamma 1
epsilon-double positive B cells.  Scand J Immunol 1994,
40:491-501.
40. Gordon S, Fraser I, Nath D, Hughes D, Clarke S: Macrophages in
tissues and in vitro. Curr Opin Immunol 1992, 4:25-32.
41. Stampfli MR, Cwiartka M, Gajewska BU, Alvarez D, Ritz SA, Inman
MD, Xing Z, Jordana M: Interleukin-10 gene transfer to the air-
way regulates allergic mucosal sensitization in mice. Am J
Respir Cell Mol Biol 1999, 21:586-596.
42. Adachi M, Oda N, Kokubu F, Minoguchi K: IL-10 induces a Th2 cell
tolerance in allergic asthma.  Int Arch Allergy Immunol 1999,
118:391-394.
43. Oh JW, Seroogy CM, Meyer EH, Akbari O, Berry G, Fathman CG,
Dekruyff RH, Umetsu DT: CD4 T-helper cells engineered to
produce IL-10 prevent allergen-induced airway hyperreac-
tivity and inflammation. J Allergy Clin Immunol 2002, 110:460-468.
44. Salez L, Singer M, Balloy V, Creminon C, Chignard M: Lack of IL-10
synthesis by murine alveolar macrophages upon lipopolysac-
charide exposure: Comparison with peritoneal
macrophages. J Leukoc Biol 2000, 67:545-552.
45. Gosset P, Tillie-Leblond I, Oudin S, Parmentier O, Wallaert B, Joseph
M, Tonnel AB: Production of chemokines and proinflamma-
tory and antiinflammatory cytokines by human alveolar
macrophages activated by IgE receptors. J Allergy Clin Immunol
1999, 103:289-297.
46. Oliver B, Tomita K, Keller A, Caramori G, Adcock I, Chung KF,
Barnes PJ, Lim S: Low-dose theophylline does not exert its anti-
inflammatory effects in mild asthma through upregulation of
interleukin-10 in alveolar macrophages.  Allergy 2001,
56:1087-1090.
47. Maloy KJ, Powrie F: Regulatory T cells in the control of immune
pathology. Nat Immunol 2001, 2:816-822.
48. Akbari O, Freeman GJ, Meyer EH, Greenfield EA, Chang TT, Sharpe
AH, Berry G, DeKruyff RH, Umetsu DT: Antigen-specific regula-
tory T cells develop via the ICOS ICOS-ligand pathway and
inhibit allergen-induced airway hyperreactivity. Nat Med 2002,
8:1024-1032.
49. Zuany-Amorim C, Sawicka E, Manlius C, Le Moine A, Brunet LR,
Kemeny DM, Bowen G, Rook G, Walker C: Suppression of airway
eosinophilia by killed Mycobacterium vaccae-induced aller-
gen-specific regulatory T-cells. Nat Med 2002, 8:625-629.